Evaluation of the potential therapeutic role of a new generation of vitamin D analog, MART-10, in human pancreatic cancer cells in vitro and in vivo

Cell Cycle

Volumn 12, Issue 8, 2013, Pages 1316-1325

  Chiang, Kun Chun ^a,b   Yeh, Chun Nan ^a   Hsu, Jun Te ^a   Yeh, Ta Sen ^a   Jan, Yi Yin ^a   Wu, Chun Te ^a   Chen, Huang Yang ^a   Jwo, Shyh Chuan ^a   Takano, Masashi ^c   Kittaka, Atsushi ^c   Juang, Horng Heng ^b   Chen, Tai C ^d  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^b CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^c TEIKYO UNIVERSITY   (Japan)

^d BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

BxPC 3; Cell cycle; Chemotherapy; MART 10; Pancreatic cancer; Vitamin D analog; Xenograft

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLIN D3; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 5; CYCLIN DEPENDENT KINASE 6; CYCLIN DEPENDENT KINASE INHIBITOR 1A; CYCLIN DEPENDENT KINASE INHIBITOR 1B; MART 10; PROTEIN TYROSINE PHOSPHATASE; UNCLASSIFIED DRUG; VITAMIN D DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CANCER PROGNOSIS; CELL FRACTIONATION; CELL PROLIFERATION; CONTROLLED STUDY; DOSE RESPONSE; DOWN REGULATION; DRUG EFFICACY; DRUG SAFETY; G1 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERCALCEMIA; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PANCREAS CARCINOMA; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TREATMENT DURATION; TUMOR GROWTH; TUMOR VOLUME; TUMOR XENOGRAFT; UPREGULATION; WEIGHT REDUCTION;

EID: 84876257196     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.24445     Document Type: Article

References (61)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013; 63:11-30; PMID:23335087; http://dx.doi.org/10.3322/caac.21166
2. Pour PM. The silent killer. Int J Pancreatol 1991; 10:103-4; PMID:1748825
3. Trede M, Schwall G, Saeger HD. Survival after pancreatoduodenectomy. 118 consecutive resections without an operative mortality. Ann Surg 1990; 211:447-58; PMID:2322039; http://dx.doi.org/10.1097/00000658-199004000-00011
4. Chiang KC, Yeh CN, Ueng SH, Hsu JT, Yeh TS, Jan YY, et al. Clinicodemographic aspect of resectable pancreatic cancer and prognostic factors for resectable cancer. World J Surg Oncol 2012; 10:77; PMID:22559838; http://dx.doi.org/10.1186/1477-7819-10-77
5. Haller DG. New perspectives in the management of pancreas cancer. Semin Oncol 2003; 30(Suppl 11):3-10; PMID:14506598; http://dx.doi.org/10.1016/S0093- 7754(03)00296-3
6. Society AC. Cancer Facts and Figures 2008. Atlanta, 2008
7. Yeo CJ, Cameron JL, Sohn TA, Lillemoe KD, Pitt HA, Talamini MA, et al. Six hundred fifty consecutive pancreaticoduodenectomies in the 1990s: Pathology, complications, and outcomes. Ann Surg 1997; 226:248-57, discussion 257-60; PMID:9339931; http://dx.doi.org/10.1097/00000658-199709000-00004
8. Nitecki SS, Sarr MG, Colby TV, van Heerden JA. Long-term survival after resection for ductal adenocarcinoma of the pancreas. Is it really improving? Ann Surg 1995; 221:59-66; PMID:7826162; http://dx.doi.org/10.1097/00000658- 199501000-00007
9. Chiang KC, Chen TC. Vitamin D for the prevention and treatment of pancreatic cancer. World J Gastroenterol 2009; 15:3349-54; PMID:19610135; http://dx.doi.org/10.3748/wjg.15.3349
10. Adams JS, Hewison M. Update in vitamin D. J Clin Endocrinol Metab 2010; 95:471-8; PMID:20133466; http://dx.doi.org/10.1210/jc.2009-1773
11. Chiang KC, Yeh CN, Chen MF, Chen TC. Hepatocellular carcinoma and vitamin D: A review. J Gastroenterol Hepatol 2011; 26:1597-603; PMID:21880026; http://dx.doi.org/10.1111/j.1440-1746.2011.06892.x
12. Chiang KC, Chen TC. The anti-cancer actions of vitamin D. Anticancer Agents Med Chem 2013; 13:126-139; PMID:23094926; http://dx.doi.org/10.2174/ 187152013804487443
13. Heikkinen S, Väisänen S, Pehkonen P, Seuter S, Benes V, Carlberg C. Nuclear hormone 1a,25-dihydroxyvitamin D3 elicits a genome-wide shift in the locations of VDR chromatin occupancy. Nucleic Acids Res 2011; 39:9181-93; PMID:21846776; http://dx.doi.org/10.1093/nar/gkr654
14. Chiang KC, Yeh CN, Chen HY, Lee JM, Juang HH, Chen MF, et al. 19-Nor-2α-(3-hydroxypropyl)-1α,25-dihydroxyvitamin D3 (MART-10) is a potent cell growth regulator with enhanced chemotherapeutic potency in liver cancer cells. Steroids 2011; 76:1513-9; PMID:21888924; http://dx.doi.org/10. 1016/j.steroids. 2011.08.006
15. Krishnan AV, Feldman D. Mechanisms of the anticancer and anti-inflammatory actions of vitamin D. Annu Rev Pharmacol Toxicol 2011; 51:311-36; PMID:20936945; http://dx.doi.org/10.1146/annurevpharmtox-010510- 100611
16. Cross HS, Kallay E. Regulation of the colonic vitamin D system for prevention of tumor progression: An update. Future Oncol 2009; 5:493-507; PMID:19450178; http://dx.doi.org/10.2217/fon.09.22
17. Welsh J. Cellular and molecular effects of vitamin D on carcinogenesis. Arch Biochem Biophys 2012; 523:107-14; PMID:22085499; http://dx.doi.org/10.1016/ j.abb.2011.10.019
18. Deeb KK, Trump DL, Johnson CS. Vitamin D signalling pathways in cancer: Potential for anticancer therapeutics. Nat Rev Cancer 2007; 7:684-700; PMID:17721433; http://dx.doi.org/10.1038/nrc2196
19. Chiang KC, Yeh CN, Chen SC, Shen SC, Hsu JT, Yeh TS, et al. MART-10, a New Generation of Vitamin D Analog, Is More Potent than 1α,25- Dihydroxyvitamin D(3) in Inhibiting Cell Proliferation and Inducing Apoptosis in ER+ MCF-7 Breast Cancer Cells. Evid Based Complement Alternat Med 2012; 2012:310872; PMID:23304196; http://dx.doi.org/10.1155/2012/310872
20. Chen TC, Holick MF. Vitamin D and prostate cancer prevention and treatment. Trends Endocrinol Metab 2003; 14:423-30; PMID:14580762; http://dx.doi.org/10.1016/j.tem.2003.09.004
21. Bouillon R, Verstuyf A, Verlinden L, Allewaert K, Branisteanu D, Mathieu C, et al. Non-hypercalcemic pharmacological aspects of vitamin D analogs. Biochem Pharmacol 1995; 50:577-83; PMID:7669059; http://dx.doi.org/10.1016/0006- 2952(95)00121-F
22. Guyton KZ, Kensler TW, Posner GH. Cancer chemoprevention using natural vitamin D and synthetic analogs. Annu Rev Pharmacol Toxicol 2001; 41:421-42; PMID:11264464; http://dx.doi.org/10.1146/annurev. pharmtox.41.1.421
23. Zugmaier G, Jäger R, Grage B, Gottardis MM, Havemann K, Knabbe C. Growth-inhibitory effects of vitamin D analogues and retinoids on human pancreatic cancer cells. Br J Cancer 1996; 73:1341-6; PMID:8645577; http://dx.doi.org/10.1038/bjc.1996.256
24. Kawa S, Nikaido T, Aoki Y, Zhai Y, Kumagai T, Furihata K, et al. Vitamin D analogues up-regulate p21 and p27 during growth inhibition of pancreatic cancer cell lines. Br J Cancer 1997; 76:884-9; PMID:9328147; http://dx.doi.org/10.1038/bjc.1997.479
25. Kawa S, Yoshizawa K, Tokoo M, Imai H, Oguchi H, Kiyosawa K, et al. Inhibitory effect of 220-oxa-1,25-dihydroxyvitamin D3 on the proliferation of pancreatic cancer cell lines. Gastroenterology 1996; 110:1605-13; PMID:8613068; http://dx.doi.org/10.1053/gast.1996. v110.pm8613068
26. Pettersson F, Colston KW, Dalgleish AG. Differential and antagonistic effects of 9-cis-retinoic acid and vitamin D analogues on pancreatic cancer cells in vitro. Br J Cancer 2000; 83:239-45; PMID:10901377
27. Colston KW, James SY, Ofori-Kuragu EA, Binderup L, Grant AG. Vitamin D receptors and anti-proliferative effects of vitamin D derivatives in human pancreatic carcinoma cells in vivo and in vitro. Br J Cancer 1997; 76:1017-20; PMID:9376260; http://dx.doi.org/10.1038/bjc.1997.501
28. Schwartz GG, Eads D, Naczki C, Northrup S, Chen T, Koumenis C. 19-nor-1 alpha,25-dihydroxyvitamin D2 (paricalcitol) inhibits the proliferation of human pancreatic cancer cells in vitro and in vivo. Cancer Biol Ther 2008; 7:430-6; PMID:18094617; http://dx.doi.org/10.4161/cbt.7.3.5418
29. Evans TR, Colston KW, Lofts FJ, Cunningham D, Anthoney DA, Gogas H, et al. A phase II trial of the vitamin D analogue Seocalcitol (EB1089) in patients with inoperable pancreatic cancer. Br J Cancer 2002; 86:680-5; PMID:11875725; http://dx.doi.org/10.1038/sj.bjc.6600162
30. Ono K, Yoshida A, Saito N, Fujishima T, Honzawa S, Suhara Y, et al. Efficient synthesis of 2-modified 1alpha,25-dihydroxy-19-norvitamin D3 with Julia olefination: High potency in induction of differentiation on HL-60 cells. J Org Chem 2003; 68:7407-15; PMID:12968893; http://dx.doi.org/10.1021/jo034787y
31. Flanagan JN, Zheng S, Chiang KC, Kittaka A, Sakaki T, Nakabayashi S, et al. Evaluation of 19-nor-2alpha-(3-hydroxypropyl)-1alpha,25-dihydroxyvitamin D3 as a therapeutic agent for androgen-dependent prostate cancer. Anticancer Res 2009; 29:3547-53; PMID:19667147
32. Chen TC, Persons KS, Zheng S, Mathieu J, Holick MF, Lee YF, et al. Evaluation of C-2-substituted 19-nor-1alpha,25-dihydroxyvitamin D3 analogs as therapeutic agents for prostate cancer. J Steroid Biochem Mol Biol 2007; 103:717-20; PMID:17207993; http://dx.doi.org/10.1016/j.jsbmb.2006.12.009
33. Iglesias-Gato D, Zheng S, Flanagan JN, Jiang L, Kittaka A, Sakaki T, et al. Substitution at carbon 2 of 19-nor-1α,25-dihydroxyvitamin D3 with 3-hydroxypropyl group generates an analogue with enhanced chemotherapeutic potency in PC-3 prostate cancer cells. J Steroid Biochem Mol Biol 2011; 127:269-75; PMID:21911059; http://dx.doi.org/10.1016/j.jsbmb.2011.08.010
34. Buras RR, Schumaker LM, Davoodi F, Brenner RV, Shabahang M, Nauta RJ, et al. Vitamin D receptors in breast cancer cells. Breast Cancer Res Treat 1994; 31:191-202; PMID:7881099; http://dx.doi.org/10.1007/BF00666153
35. Jaruga E, Salvioli S, Dobrucki J, Chrul S, Bandorowicz-Pikuła J, Sikora E, et al. Apoptosis-like, reversible changes in plasma membrane asymmetry and permeability, and transient modifications in mitochondrial membrane potential induced by curcumin in rat thymocytes. FEBS Lett 1998; 433:287-93; PMID:9744813; http://dx.doi.org/10.1016/S0014-5793(98)00919-3
36. Colston KW, Mackay AG, James SY, Binderup L, Chander S, Coombes RC. EB1089: A new vitamin D analogue that inhibits the growth of breast cancer cells in vivo and in vitro. Biochem Pharmacol 1992; 44:2273-80; PMID:1472092; http://dx.doi.org/10.1016/0006-2952(92)90669-A
37. Danielsson C, Mathiasen IS, James SY, Nayeri S, Bretting C, Hansen CM, et al. Sensitive induction of apoptosis in breast cancer cells by a novel 1,25-dihydroxyvitamin D3 analogue shows relation to promoter selectivity. J Cell Biochem 1997; 66:552-62; PMID:9282333; http://dx.doi.org/10.1002/(SICI)1097- 4644(19970915)66:4<552::AIDJCB14> 3.0.CO;2-D
38. Mathiasen IS, Colston KW, Binderup L. EB 1089, a novel vitamin D analogue, has strong antiproliferative and differentiation inducing effects on cancer cells. J Steroid Biochem Mol Biol 1993; 46:365-71; PMID:9831485; http://dx.doi.org/10.1016/0960-0760(93)90226-M
39. Hansen CM, Mäenpää PH. EB 1089, a novel vitamin D analog with strong antiproliferative and differentiation-inducing effects on target cells. Biochem Pharmacol 1997; 54:1173-9; PMID:9416968; http://dx.doi.org/10. 1016/S0006-2952(97)00181-0
40. Vink-van Wijngaarden T, Pols HA, Buurman CJ, van den Bemd GJ, Dorssers LC, Birkenhäger JC, et al. Inhibition of breast cancer cell growth by combined treatment with vitamin D3 analogues and tamoxifen. Cancer Res 1994; 54:5711-7; PMID:7923220
41. James SY, Mercer E, Brady M, Binderup L, Colston KW. EB1089, a synthetic analogue of vitamin D, induces apoptosis in breast cancer cells in vivo and in vitro. Br J Pharmacol 1998; 125:953-62; PMID:9846632; http://dx.doi.org/10.1038/ sj.bjp.0702103
42. Lokeshwar BL, Schwartz GG, Selzer MG, Burnstein KL, Zhuang SH, Block NL, et al. Inhibition of prostate cancer metastasis in vivo: A comparison of 1,23-dihydroxyvitamin D (calcitriol) and EB1089. Cancer Epidemiol Biomarkers Prev 1999; 8:241-8; PMID:10090302
43. Gulliford T, English J, Colston KW, Menday P, Moller S, Coombes RC. A phase I study of the vitamin D analogue EB 1089 in patients with advanced breast and colorectal cancer. Br J Cancer 1998; 78:6-13; PMID:9662243; http://dx.doi.org/10.1038/bjc.1998.434
44. Nickerson T, Huynh H. Vitamin D analogue EB1089-induced prostate regression is associated with increased gene expression of insulin-like growth factor binding proteins. J Endocrinol 1999; 160:223-9; PMID:9924191; http://dx.doi.org/10.1677/joe.0.1600223
45. Albrechtsson E, Jonsson T, Möller S, Höglund M, Ohlsson B, Axelson J. Vitamin D receptor is expressed in pancreatic cancer cells and a vitamin D3 analogue decreases cell number. Pancreatology 2003; 3:41-6; PMID:12649563; http://dx.doi.org/10.1159/000069149
46. Saito N, Honzawa S, Kittaka A. Recent results on A-ring modification of 1alpha,25-dihydroxyvitamin D3: Design and synthesis of VDR-agonists and antagonists with high biological activity. Curr Top Med Chem 2006; 6:1273-88; PMID:16848741; http://dx.doi.org/10.2174/156802606777864953
47. Hourai S, Fujishima T, Kittaka A, Suhara Y, Takayama H, Rochel N, et al. Probing a water channel near the A-ring of receptor-bound 1 alpha,25- dihydroxyvitamin D3 with selected 2 alpha-substituted analogues. J Med Chem 2006; 49:5199-205; PMID:16913708; http://dx.doi.org/10.1021/jm0604070
48. Suhara Y, Nihei KI, Kurihara M, Kittaka A, Yamaguchi K, Fujishima T, et al. Efficient and versatile synthesis of novel 2alpha-substituted 1alpha,25-dihydroxyvitamin D(3) analogues and their docking to vitamin D receptors. J Org Chem 2001; 66:8760-71; PMID:11749604; http://dx.doi.org/10. 1021/jo010375i
49. Annalora AJ, Goodin DB, Hong WX, Zhang Q, Johnson EF, Stout CD. Crystal structure of CYP24A1, a mitochondrial cytochrome P450 involved in vitamin D metabolism. J Mol Biol 2010; 396:441-51; PMID:19961857; http://dx.doi.org/10. 1016/j.jmb.2009.11.057
50. Powers JT, Hong S, Mayhew CN, Rogers PM, Knudsen ES, Johnson DG. E2F1 uses the ATM signaling pathway to induce p53 and Chk2 phosphorylation and apoptosis. Mol Cancer Res 2004; 2:203-14; PMID:15140942
51. Krtolica A, Krucher NA, Ludlow JW. Hypoxia-induced pRB hypophosphorylation results from downregulation of CDK and upregulation of PP1 activities. Oncogene 1998; 17:2295-304; PMID:9811460; http://dx.doi.org/10.1038/ sj.onc.1202159
52. Fan FS, Yu WC. 1,25-Dihydroxyvitamin D3 suppresses cell growth, DNA synthesis, and phosphorylation of retinoblastoma protein in a breast cancer cell line. Cancer Invest 1995; 13:280-6; PMID:7743381; http://dx.doi.org/10.3109/ 07357909509094463
53. Jensen SS, Madsen MW, Lukas J, Binderup L, Bartek J. Inhibitory effects of 1alpha,25-dihydroxyvitamin D(3) on the G(1)-S phase-controlling machinery. Mol Endocrinol 2001; 15:1370-80; PMID:11463860; http://dx.doi.org/10.1210/me.15. 8.1370
54. Harper JW, Elledge SJ. Cdk inhibitors in development and cancer. Curr Opin Genet Dev 1996; 6:56-64; PMID:8791491; http://dx.doi.org/10.1016/S0959- 437X(96)90011-8
55. Sherr CJ, Roberts JM. CDK inhibitors: Positive and negative regulators of G1-phase progression. Genes Dev 1999; 13:1501-12; PMID:10385618; http://dx.doi.org/10.1101/gad.13.12.1501
56. Meeran SM, Katiyar SK. Cell cycle control as a basis for cancer chemoprevention through dietary agents. Front Biosci 2008; 13:2191-202; PMID:17981702; http://dx.doi.org/10.2741/2834
57. Blanke CD, Beer TM, Todd K, Mori M, Stone M, Lopez C. Phase II study of calcitriol-enhanced docetaxel in patients with previously untreated metastatic or locally advanced pancreatic cancer. Invest New Drugs 2009; 27:374-8; PMID:18843448; http://dx.doi.org/10.1007/s10637-008-9184-6
58. Chen TC, Schwartz GG, Burnstein KL, Lokeshwar BL, Holick MF. The in vitro evaluation of 25-hydroxyvitamin D3 and 19-nor-1alpha,25-dihydroxyvitamin D2 as therapeutic agents for prostate cancer. Clin Cancer Res 2000; 6:901-8; PMID:10741714
59. Chen TC, Persons K, Liu WW, Chen ML, Holick MF. The antiproliferative and differentiative activities of 1,25-dihydroxyvitamin D3 are potentiated by epidermal growth factor and attenuated by insulin in cultured human keratinocytes. J Invest Dermatol 1995; 104:113-7; PMID:7798628; http://dx.doi.org/10.1111/1523-1747.ep12613601
60. Ouyang W, Ma Q, Li J, Zhang D, Liu ZG, Rustgi AK, et al. Cyclin D1 induction through IkappaB kinase beta/nuclear factor-kappaB pathway is responsible for arsenite-induced increased cell cycle G1-S phase transition in human keratinocytes. Cancer Res 2005; 65:9287-93; PMID:16230390; http://dx.doi.org/10.1158/0008-5472.CAN-05-0469
61. Vermes I, Haanen C, Reutelingsperger C. Flow cytometry of apoptotic cell death. J Immunol Methods 2000; 243:167-90; PMID:10986414; http://dx.doi.org/10. 1016/S0022-1759(00)00233-7